Biomea Fusion (BMEA) announced that the first patient has been dosed in a Phase I clinical trial of BMF-650, the Company’s investigational, next-generation oral small molecule glucagon-like peptide-1 receptor agonist. BMF-650 is an orally administered, next-generation small molecule GLP-1 RA being developed by Biomea for the treatment of obesity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion’s Promising Clinical Trials and Strategic Advancements Drive Buy Rating
- Positive Outlook for Biomea Fusion: Promising Phase 2 Results for Icovamenib in Type 2 Diabetes Treatment
- Biomea Fusion Enters Underwriting Agreement with Jefferies
- Biomea Fusion prices 11.2M shares at $2.05 in public offering
- Closing Bell Movers: Constellation Brands up 3% on earnings beat